Edition:
United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

74.60EUR
9:39am EDT
Change (% chg)

€-0.51 (-0.68%)
Prev Close
€75.12
Open
€75.82
Day's High
€75.82
Day's Low
€74.60
Volume
521
Avg. Vol
990
52-wk High
€81.91
52-wk Low
€60.60

Latest Key Developments (Source: Significant Developments)

Eli Lilly says got civil investigative demand from U.S. Attorney’s office for southern district of New York
1:48pm EDT 

Eli Lilly : Received a civil investigative demand from the u.s. attorney’s office for southern district of New York - Filing . Civil investigative demand related to documents and information relating to our contracts with, services performed by and payments to pharmacy benefit managers- filing .Eli Lilly says "we are cooperating with this investigation".  Full Article

Eli Lilly says CEO John Lechleiter to retire
Wednesday, 27 Jul 2016 06:45am EDT 

Eli Lilly And Co : On July 27, John Lechleiter announced retirement as president and chief executive officer . Lechleiter will also retire as chairman and a member of board of directors, effective may 31, 2017 .Board elected David Ricks as president and chief executive officer of company.  Full Article

Eli Lilly reports quarterly earnings of $0.71 per share
Tuesday, 26 Jul 2016 07:05am EDT 

Eli Lilly And Co : Q2 earnings per share $0.71 . Q2 non-gaap earnings per share $0.86 . . Q2 earnings per share view $0.86 -- Thomson Reuters I/B/E/S . For Q2 of 2016, alimta generated revenues of $607.1 million, a decline of 9 percent . Revenues for jardiance during Q2 of 2016 were $40.1 million. u.s. Revenues were $26.0 million . Jardiance revenues for Q2 driven by growth in SGLT2 class and increased share of market for Jardiance . Reaffirmed its commitment to achieve an opex-to-revenue ratio of 50 percent or less in 2018 . Eli Lilly and co sees 2016 capital expenditures of about $1.1 billion . Quarterly Research & Development Expenses Increased 14 percent To $1.336 billion, Driven Primarily By Higher Late stage clinical development costs . FY2016 earnings per share view $3.56, revenue view $20.92 billion -- Thomson Reuters I/B/E/S . Reaffirming commitment to achieve an opex-to-revenue ratio of 50 percent or less in 2018 . Quarter 2016 results, provides financial expectations through the remainder of the decade . Reaffirms FY2016 non-gaap earnings per share view $3.50 to $3.60 . Reaffirms FY 2016 earnings per share view $2.68 to $2.78 . Q2 revenue $5.405 billion versus I/B/E/S view $5.15 billion . Company confirms 2016 EPS to be in range of $2.68 to $2.78 (reported) . Eli lilly and co sees 2016 revenue $20.6 to $21.1 billion . Eli lilly and co quarterly Cymbalta sales $236.5 million, down 14 percent.  Full Article

Eli Lilly CEO John Lechleiter says view a future where drug pricing is going to be challenging across the board- CNBC
Tuesday, 26 Jul 2016 07:00am EDT 

: Eli Lilly CEO John Lechleiter says view a future where drug pricing is going to be challenging across the board - CNBC (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780).  Full Article

Eli Lilly Canada says Health Canada approves Taltz for treatment of moderate-to-severe plaque psoriasis
Tuesday, 21 Jun 2016 12:42pm EDT 

Eli Lilly Canada :Eli Lilly Canada says Health Canada has granted approval for Taltz for treatment of moderate-to-severe plaque psoriasis.  Full Article

Eli Lilly sets quarterly dividend of $0.51/shr
Monday, 20 Jun 2016 01:00pm EDT 

Eli Lilly And Co :Sets quarterly dividend of $0.51 per share.  Full Article

Eli Lilly and Co says German supreme court grants Lilly appeal in Alimta vitamin regimen patent lawsuit
Tuesday, 14 Jun 2016 06:15pm EDT 

Eli Lilly And Co : Eli lilly and co says german supreme court grants lilly appeal in alimta vitamin regimen patent lawsuit . Eli lilly and co says german supreme court returned case to court of appeal ( dusseldorf ) for further proceedings . Separate infringement proceeding and validity challenge with hexal ag will continue unaffected by this ruling . Eli lilly and co says separate infringement proceeding and validity challenge with hexal ag will continue unaffected by this ruling .German federal supreme court has granted appeal by eli lilly in case of eli lilly v. Actavis, vacating prior decision denying infringement.  Full Article

Lilly names Aarti Shah Chief Information Officer
Monday, 13 Jun 2016 01:00pm EDT 

Eli Lilly And Co: Aarti Shah named Chief Information Officer . Promotion of Aarti Shah , Ph.D., to Senior Vice President and Chief Information Officer effective July 1 .Shah has been global brand development leader for Immunology since 2013..  Full Article

Lilly says announces results from Monarch 1 trial of Abemaciclib monotherapy
Friday, 3 Jun 2016 05:45pm EDT 

Eli Lilly And Co - : Says safety and toxicity profile continuously dosed Abemaciclib was consistent with previous Phase 1 experience . Lilly announces results from monarch 1 trial of Abemaciclib monotherapy .Eli Lilly and Co says plans to publish further data from monarch 1 trial later this year.  Full Article

Adocia, Lilly announce positive results from BioChaperone Lispro U100 study
Tuesday, 31 May 2016 12:00pm EDT 

Eli Lilly And Co : Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin biochaperone lispro U100 in healthy Japanese subjects .Both BioChaperone Lispro and Humalog were similarly well tolerated; no new or unexpected safety findings were observed..  Full Article

U.S. probes contracts between Eli Lilly and PBMs

Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).